Clinical Trials Browser

Phase 1/2 × Metastatic Hormone-Sensitive Prostate Cancer × Genitourinary × Clear all

NCT03343977 2018-07-17

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Phase 1/2 Withdrawn

Metastatic Hormone-Sensitive Prostate Cancer